Deep Genomics

Edit info

Founded: 2014

Location: Toronto, ON

Employee range: 50 - 200

Clinical stage: RD

Therapy area: CNS conditions

Drug types: NEU, GEN

Lead product: Undisclosed

Funding: $40M B Jan 2020

Investors: Future Ventures, Amplitude Ventures, Magnetic Ventures, Khosla Ventures, True Ventures

deepgenomics.com

linkedin.com

job board

Business:

AI-discovery, Oligonucleotide Therapies

Drug notes:

Additional undisclosed programs RD CNS conditions, metabolic conditions, undisclosed

About:

Deep Genomics is using AI to build life-saving genetic therapeutics. Biology is too complex for the human mind to comprehend, so future drug development will depend on AI assistance. By using the revolutions in AI, RNA biology and automation, Deep Genomics is designing RNA therapies for any gene and any genetic condition. Deep Genomics’ proprietary AI Workbench identifies novel targets from evaluating thousands of possibilities to identify the best therapeutic candidates. Lead candidates have been identified for over 50% of the novel targets Deep Genomics has tested so far. Now, Deep Genomics is creating AI Workbench 3.0 to expand the number of mechanisms and genetic variants analyzed, so the company can tackle complex genetic diseases.